CAT and Abbott: A David and Goliath Story
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 56 (Table of Contents)
Published: 1 Feb-2005
DOI: 10.3833/pdr.v2005.i56.722 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Following a legal victory over Abbott Laboratories, Cambridge Antibody Technology (CAT) will now receive royalties on the rheumatoid arthritis therapeutic Humira#174; (adalimumab), at a rate more than double the one it was receiving before...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS